ABSTRACT
In Burkina Faso, western Africa country, malnutrition is an underlying cause of 35% of deaths among children under 5 years of age. In the health district of Dano, south-west region where the prevalence of chronic malnutrition among children under five exceeds the WHO threshold (30%), ProgettoMondo Mlal, an Italian non-governmental organization, has put in place a mechanism to strengthen the Community system in order to carry out actions for promoting good practices in infant and young child feeding (IYCF) and community management of acute malnutrition at village level. Nutrition Educational Cells (NEC) supported by village nutrition committees (VNCs) were set up in 99 villages of the district. The one-year results show improved knowledge of good IYCF practices at mothers level, an increase in the number of acute malnutrition cases detected and referred to health centers and better participation of local communities in the implementation and financing nutrition actions. In view of the results achieved, the NEC strategy could be an opportunity to strengthen the resilience of communities to the under-nutrition of children under 5 years of age.
Subject(s)
AIDS-Related Opportunistic Infections/chemically induced , Antiretroviral Therapy, Highly Active/adverse effects , HIV Infections/drug therapy , HIV-1 , Meningitis, Cryptococcal/chemically induced , AIDS-Related Opportunistic Infections/drug therapy , Adult , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Female , Humans , Magnetic Resonance Imaging/methods , Male , Meningitis, Cryptococcal/drug therapySubject(s)
BCG Vaccine/adverse effects , Carcinoma, Transitional Cell/microbiology , Hepatitis/microbiology , Mycobacterium bovis/growth & development , Sepsis/microbiology , Urinary Bladder Neoplasms/microbiology , Aged , BCG Vaccine/therapeutic use , Carcinoma, Transitional Cell/therapy , Humans , Male , Urinary Bladder Neoplasms/therapyABSTRACT
We studied factors associated with treatment adherence in 88 male and 21 female adults (age range, 24-65 years) with HIV infection undergoing therapy with HIV-1 protease inhibitors (PIs) in Italy. Data on sociodemographic variables, clinical and psychological symptoms, treatment compliance, physician/patient relationship, and psychosocial characteristics were obtained by means of semistructured interviews. Every subject also compiled two self-report questionnaires: Coping Orientations to Problem Experiences (COPE) and Medical Outcomes Study-HIV (MOS-HIV) in order to evaluate the use of coping strategies and quality of life. We found a high rate of adherence to HIV therapies (almost 90% of patients had taken at least 80% of medication in the previous 7 days). No significant differences were found between adherence and nonadherence groups as measured by self-report. Few significant differences were found when data laboratory were used. When a Bonferroni corrected p level of <0.001 was used, only a comparison on Mental Disengagement subscale of COPE was statistically significant.
Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , HIV Infections/psychology , HIV Protease Inhibitors/administration & dosage , Patient Compliance , Adaptation, Psychological , Adult , Aged , Female , HIV-1 , Humans , Interviews as Topic , Italy , Male , Middle Aged , Quality of Life , Surveys and QuestionnairesABSTRACT
Synercid (quinupristin/dalfopristin), the first semi-synthetic injectable streptogramin, is a promising alternative to glycopeptides against many Gram-positive multiresistant bacteria. Vancomycin is still considered an effective agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections but therapeutic failures with glycopeptides have been observed, even for the treatment of infections caused by S. aureus strains sensitive to vancomycin. Synercid, in combination with a glycopeptide, may address this problem without causing significant side effects due to the different toxicity patterns of the 2 antimicrobials. This study reports our experience with the combination of Synercid and vancomycin in 5 patients with severe infection caused by MRSA or methicillin-resistant coagulase-negative Staphylococcus.